Artivion Q2 Earnings Call Highlights
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) Q2 Earnings Meet Estimates
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion Q1 Earnings Call Highlights
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.
Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates
Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Secures FDA Approval for NEXUS Aortic Arch System
AORT jumps after FDA approves NEXUS Aortic Arch System, unlocking a potential Endospan acquisition and advancing minimally invasive care for high-risk patients.
Artivion (AORT) Soars 5.3%: Is Further Upside Left in the Stock?
Artivion (AORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) Q4 Earnings Surpass Estimates
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.
Artivion Continues Building Toward Bigger And Better Things
Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance.
